Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elenestinib (Primary)
  • Indications Systemic mastocytosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HARBOR
  • Sponsors Blueprint Medicines

    • Most Recent Events

    • 01 Jul 2024 Number of arms changed from 9 to 10. Experimental: (Part S) Elenestinib + BSC added to study protocol.
    • 04 May 2024 Planned number of patients changed from 443 to 463.
    • 12 Dec 2023 Results (As of data cutoff on July 3, 2023, n=122) assessing safety of Elenestinib in Patients with Indolent Systemic Mastocytosis presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top